GeneBioTech Co. ,Ltd (KOSDAQ:086060)
South Korea · Delayed Price · Currency is KRW 4,825.00
0.00 (0.00%)
At close: Sep 11, 2026
GeneBioTech Co. ,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 89,315 | 90,789 | 82,959 | 79,477 | 82,759 | 62,814 |
Other Revenue | 0 | - | - | - | -0 | -0 |
| 89,315 | 90,789 | 82,959 | 79,477 | 82,759 | 62,814 | |
Revenue Growth | 0.97% | 9.44% | 4.38% | -3.96% | 31.75% | 6.25% |
Cost of Revenue | 74,028 | 76,533 | 69,589 | 65,825 | 72,409 | 55,374 |
Gross Profit | 15,287 | 14,256 | 13,370 | 13,652 | 10,349 | 7,439 |
Selling, General & Admin | 9,216 | 8,845 | 8,285 | 8,411 | 7,446 | 6,472 |
Research & Development | 925.79 | 894.56 | 875.1 | 837.22 | 765.04 | 820.81 |
Amortization of Goodwill & Intangibles | 67.12 | 67.9 | 65.9 | 63.18 | 39.68 | 12.16 |
Other Operating Expenses | 99.84 | 92.32 | 102.78 | 104.84 | 108.26 | 106.95 |
Operating Expenses | 10,678 | 10,260 | 9,526 | 9,679 | 8,792 | 7,893 |
Operating Income | 4,609 | 3,996 | 3,844 | 3,973 | 1,557 | -453.15 |
Interest Expense | -538.13 | -562.44 | -642.98 | -581.38 | -276.45 | -152 |
Interest & Investment Income | 788.78 | 777.74 | 800.59 | 669.56 | 263.92 | 127.25 |
Currency Exchange Gain (Loss) | -648.07 | 129.98 | -639.97 | -138.66 | 23.26 | -223.24 |
Other Non Operating Income (Expenses) | 82.77 | 74.01 | 19.06 | 20.65 | 247.09 | -129.9 |
EBT Excluding Unusual Items | 4,295 | 4,415 | 3,380 | 3,943 | 1,815 | -831.03 |
Gain (Loss) on Sale of Assets | 11.36 | -0.15 | 122.26 | 20.69 | -0 | -5.88 |
Asset Writedown | - | - | - | -589.54 | - | - |
Other Unusual Items | - | - | - | - | - | -0.85 |
Pretax Income | 4,306 | 4,415 | 3,503 | 3,374 | 1,815 | -837.76 |
Income Tax Expense | 634.16 | 625.88 | 637.3 | 782.7 | 291.39 | -353.36 |
Earnings From Continuing Operations | 3,672 | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 |
Net Income to Company | 3,672 | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 |
Net Income | 3,672 | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 |
Net Income to Common | 3,672 | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 |
Net Income Growth | 2.05% | 32.23% | 10.57% | 70.12% | - | - |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | 9 |
Shares Change | -0.09% | 0.07% | -0.07% | - | - | - |
EPS (Basic) | 427.00 | 440.02 | 333.00 | 300.95 | 176.91 | -56.26 |
EPS (Diluted) | 427.00 | 440.02 | 333.00 | 300.95 | 176.91 | -56.26 |
EPS Growth | 2.14% | 32.14% | 10.65% | 70.12% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 4,525 | 3,856 | -1,564 | 6,838 | -4,834 | -5,816 |
Free Cash Flow Per Share | 526.18 | 447.87 | -181.81 | 794.19 | -561.41 | -675.39 |
Gross Margin | 17.12% | 15.70% | 16.12% | 17.18% | 12.50% | 11.84% |
Operating Margin | 5.16% | 4.40% | 4.63% | 5.00% | 1.88% | -0.72% |
Profit Margin | 4.11% | 4.17% | 3.45% | 3.26% | 1.84% | -0.77% |
Free Cash Flow Margin | 5.07% | 4.25% | -1.89% | 8.60% | -5.84% | -9.26% |
EBITDA | 5,954 | 5,382 | 5,212 | 5,311 | 2,843 | 791.25 |
EBITDA Margin | 6.67% | 5.93% | 6.28% | 6.68% | 3.44% | 1.26% |
D&A For EBITDA | 1,344 | 1,387 | 1,368 | 1,338 | 1,286 | 1,244 |
EBIT | 4,609 | 3,996 | 3,844 | 3,973 | 1,557 | -453.15 |
EBIT Margin | 5.16% | 4.40% | 4.63% | 5.00% | 1.88% | -0.72% |
Effective Tax Rate | 14.73% | 14.18% | 18.20% | 23.20% | 16.06% | - |
Advertising Expenses | - | 109.97 | 127.26 | 54.49 | 429.28 | 429.72 |